Q-omics provides the consensus-scored POLR3F profile across patient tissues and cancer cell-line models. POLR3F expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, POLR3F is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, POLR3F protein abundance shows 20,586 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, HNSC, and LSCC as cancer lineages where POLR3F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR3F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR3F survival associations across molecular data types. POLR3F RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR3F RNA expression–survival associations across cancer types. High POLR3F expression shows unfavorable associations in LIHC, MESO, CESC, KICH and SCLC, but favorable associations in KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for POLR3F RNA expression.
This table summarizes POLR3F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR3F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR3F shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, COAD, STAD and BRCA. The HNSC box plot shows higher POLR3F RNA expression in tumor versus normal tissue (log2 FC = +0.796, t-test p < 0.001).
This table shows molecular features associated with POLR3F in patient tissues and cancer cell lines. In patient samples, POLR3F shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR3F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
